The Johns Hopkins University spinout's MycoMeia Aspergillus Assay is used to aid the diagnosis of the lung disease aspergillosis in immunocompromised patients.

The firm said it is in talks with payors about pilot programs and it expects to soon publish data on the use of its test to improve outcomes and reduce healthcare costs.

The company also announced it would be divesting its Exosome Diagnostics business and selling it to MDxHealth.

The firm saw an increase in diagnostics solutions sales in the second quarter, particularly within its QuantiFeron and QiaStat-Dx businesses.

The firm anticipates lower-than-previously-expected COVID test sales will be offset by shifts in trade policy and tariff mitigation efforts.

As part of the deal, the company is acquiring a "significant library of potential applications" of the test's exosome-based technology.

Stakeholders suggested that while the FDA rule is dead, updates to LDT regulation are coming, nonetheless, and the industry ...

Danaher subsidiaries Beckman Coulter, Cepheid, and Leica Biosystems will be working together with external partners to focus ...

The South Korean firm said that its CURECA system offers walkaway PCR testing with 24/7 operation without human intervention ...

Including its COVID-19-related business, the company's second quarter revenues were down 43 percent year over year.

At ADLM, the company provided a preview of its Liaison Nes point-of-care PCR instrument that is complementary to the firm's Liaison Plex syndromic testing system.

Developed as part of a broader collaboration between the two firms, the tool uses generative AI to let providers ask questions and describe conditions in plain language.